2023年6月19日

Metagen治療完成首輪融資籌集17億日圓Metagen療法,公司專注於藥物發現和開發基於腸道microbiome-based治療各種疾病,已經完成了係列2輪融資,籌集17億日圓。Sparx Asset Management,日本風險資本,瑞穗資本和風險資本SMBC加入了第一輪投資者標準件的JIC風險增長投資,一種主權財富基金在日本,JAFCO,日本最大的風險資本公司,快車道倡議和慶應義塾創新計劃。第二輪的關閉,Metagen療法提出了總額19.3億日元自成立以來。融資的目的已經被越來越多的運動,利用近年來腸道細菌在醫學領域。在澳大利亞和美國等國家,“糞便微生物群移植(FMT)”已被實現為一個醫療過程,並在2023年4月,美國食品藥品管理局批準了世界上第一個stool-derived口腔微生物藥物配方。最新的融資,Metagen療法旨在實現三個目標:腸道菌群的建設和運營,研究和開發微生物群的藥物發現項目,和社會FMT的實現。通過建立腸道微生物群銀行在日本我們將能夠連接病人和捐助者,這反過來將支持和促進FMT的社會實現,並從那裏幫助開發具有國際競爭力的微生物藥物源於日本。使用基金・登記製度的發展為腸道菌群捐贈候選人・操作腸道微生物群的銀行(按照機構指南)——捐贈招聘/在線訪談,捐贈資格評估,攝入的凳子上捐款,製造/評估/存儲的腸道微生物群解決・為腸道菌群建立關於製備過程和質量控製解決方案2。推廣臨床應用的基礎和臨床研究FMT(如聯合研究與免疫抑製劑檢查站)3。研究和development of intestinal microbiota drug discovery program (including probiotics) June 15th marks the final close of our Series A funding round, raising a total of 1.7 billion yen. We are very grateful for the deep trust and support of our top-tier investors, including FTI, JAFCO, and KII, who have supported us since the Seed and Pre-A rounds, JIC-VGI, who participated in the Series A First Close in April, and SPARX, NVCC, Mizuho Capital, and SMBC Venture Capital, who joined us at this final close. This funding will provide a powerful boost to expand the impact of microbiome medicine and drug discovery from Japan to the rest of the world, working to fulfill our mission of “Living up to the hopes of patients through microbiome science”. Intestinal microbiome therapy is entering a new phase globally, with the approval of stool-derived oral formulations in the United States. We are determined not to miss this trend and renew our strong determination to bring advanced treatments to patients in Japan as soon as possible. Said Taku Nakahara, President and CEO, Metagen Therapeutics.